title: Ten years single institutional experience of treatment for advanced laryngeal cancer in Kyoto University.
abstract: CONCLUSIONS
  It is important to suppress lymph node recurrence and distant metastasis to achieve better survival of advanced laryngeal cancer, especially supraglottic cancer.
  
  
  OBJECTIVE
  The therapeutic outcomes of 33 cases with advanced laryngeal cancer treated at Kyoto University Hospital between 2000 and 2008 were reviewed.
  
  
  METHODS
  Thirty-one males and two females were involved. Their ages ranged from 49 to 81 years (average 65.6 years). All tumors were squamous cell carcinoma, arising at the glottis in 21 cases and the supraglottis in 12 cases. Most glottic cancers (90.5%) and supraglottic cancers (83.3%) were classified as T3 or T4. Total laryngectomy with neck dissection was performed in the treatment of T3 or T4 cases. Two cases of T2 cancers were treated by radiotherapy (66-72 Gy) with neck dissection, and one case of T2 cancer was treated by radiotherapy (66 Gy). Partial laryngectomy with neck dissection was performed in one T3 case.
  
  
  RESULTS
  Five-year overall survival rates for stage III of glottic cancer, stage IV of glottic cancer, stage III of supraglottic cancer, and stage IV of supraglottic cancer were 100%, 40.9%, 100%, and 24.2%, respectively. Five-year disease-specific survival rates for stage III of glottic cancer, stage IV of glottic cancer, stage III of supraglottic cancer, and stage IV of supraglottic cancer were 100%, 56.3%, 100%, and 28.1%, respectively. No local recurrence occurred. Regional lymph node recurrence occurred in two cases- one patient with glottic cancer and one with supraglottic cancer. Both of them died of disease despite undergoing chemotherapy. One case initially had lung metastasis, and post-treatment distant metastasis occurred in the lung in four cases, in the skin in one, and in multiple organs in one case.
authors.affiliation: Department of Otolaryngology-Head & Neck Surgery, Kyoto University, Kyoto, Japan. skada@ent.kuhp.kyoto-u.ac.jp
authors.forename: Shinpei
authors.initials: S
authors.lastname: Kada
authors.forename: Shigeru
authors.initials: S
authors.lastname: Hirano
authors.forename: Ichiro
authors.initials: I
authors.lastname: Tateya
authors.forename: Morimasa
authors.initials: M
authors.lastname: Kitamura
authors.forename: Seiji
authors.initials: S
authors.lastname: Ishikawa
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kanda
authors.forename: Ryo
authors.initials: R
authors.lastname: Asato
authors.forename: Shinzo
authors.initials: S
authors.lastname: Tanaka
authors.forename: Juichi
authors.initials: J
authors.lastname: Ito
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006785:Hospitals, University; D006801:Humans; D007564:Japan; D007822:Laryngeal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D007825:Laryngectomy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome